| Ytd | 59.99% | |
| 1y | 205.23% |
| Open | 39.15 | Prev Close | 39.15 | Low | 38.78 | High | 39.81 | Mkt Cap | 4.26B |
| Vol | 138.50K | Avg Vol | 1.41M | EPS | -1.66 | P/E | N/A | Forward P/E | -27.48 |
| Beta | 0.30 | Short Ratio | 7.08 | Inst. Own | 113.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 34.86 | 200-d Avg | 27.01 | 1yr Est | 48.17 |
EWTX News
BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperfo
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial i
Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D
Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart
HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWT
Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –– Consi
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Cons
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of
BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture d
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperfo
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and r
Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy
The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial
— Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading m
– Announced positive long-term sevasemten data demonstrating sustained functional stabilization in
Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidanc
BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"
ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Edgewise Therapeutics (NASDAQ: EWTX - Get Free R
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesda
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average ra
SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWT
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares o
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Compan
She raised her price target by $11 per share. In her view, the company's No.
Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for
